Following the first public presentation of NBE-Therapeutics at the Swiss Biotech Day on April 9, 2013, NBE-Therapeutics was featured as a highly promising new Swiss start-up company in the Economy section of the reputable Swiss national newspaper "Neue Züricher Zeitung am Sonntag" (NZZ a.S.). The featured article mentions that NBE-Therapeutics works in one of "...the hottest areas in the pharmaceutical industry: the improvement of existing cancer therapies by combining different treatment principles in one drug." namely the "...coupling of a cellular toxin to a monoclonal antibody." This creates so-called antibody drug conjugates (ADCs), in which the cellular toxin is specifically targeted to cancer cells using the highly selective binding properties of monoclonal antibodies to desired cellular targets. The articles continues that NBE Therapeutics has developed a "...technology that allows the precise conjugation of cellular toxins with antibodies...", which indeed represents an improvement to currently applied random chemical conjugations of small molecule toxins to antibodies that result in difficulties in the manufacturing of ADC drug candidates.